Pain Comparison Whit Visual Analog Scale (EVA) Between Four Analgesic Methods During Trans Rectal Prostatic Biopsy

Sponsor
Instituto Mexicano del Seguro Social (Other)
Overall Status
Completed
CT.gov ID
NCT03442075
Collaborator
(none)
70
1
3
23.4

Study Details

Study Description

Brief Summary

Define the best analgesic method between peri prostatic blockage, analgesic suppository, oral analgesic and topic anesthetic gel, during trans rectal prostate biopsy

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Comparison between four analgesic methods during trans rectal prostatic biopsy.

    OBJECTIVE: To define the best analgesic method between the peri-prostatic block, the analgesic suppository, the oral analgesic, the final anesthetic gel, during the trans rectal prostate biopsy determined at the end of the procedure with a visual analogue scale for pain (VAS pain) in a Interview 15 to 30 minutes at the end of the procedure.

    METHODS: experimental, retrospective, longitudinal, comparative, during May to July 2017, 350 trans rectal prostate biopsies were performed, all cases were randomly assigned to one of the four study groups. The data analysis will be performed by calculating measures of central tendency and dispersion for quantitative variables and ANOVA test, for qualitative variables Chi square to determine statistical differences between the three moments of pain in the parameters of introduction of the ultrasound transducer, sampling of Prostate of the minimum 12 biopsies and discomfort in general of the procedure

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    70 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Prospective, Controlled, Randomized Clinical Trial to Evaluate the Effectiveness of Four Analgesic Methods During Trans Rectal Prostate Biopsy.
    Actual Study Start Date :
    May 1, 2017
    Actual Primary Completion Date :
    Jul 31, 2017
    Actual Study Completion Date :
    Jul 31, 2017

    Arms and Interventions

    Arm Intervention/Treatment
    Group 1

    Group 1 an analgesic suppository was applied

    Group 2

    Group 2 was administered analgesic orally

    Group 3

    Group 3 was given trans rectal gel

    Group 4

    Group was performed peri prostatic infiltration.

    Group 5

    Group was performed by placebo oral

    Outcome Measures

    Primary Outcome Measures

    1. Ultrasound Transducer [Interview 15 to 30 minutes at the end of the procedure]

      Evaluation of the discomfort or pain in the introduction of the trans rectal ultrasound transducer determined at the end of the procedure with Visual Analog Scale for Pain, which is a psychometric measuring instrument designed to assess the pain intensity experienced by each patient individually. Was employ for first time in 1921 and referred as a "graphical rating method", which has the characteristic of being able to achieve a rapid classification (statistically measurable and reproducible) of the severity of pain experience. The analogous visual scale used for this study measures from 0-10 the intensity of the pain with a series of "faces" that show the intensity in the pain experimentation with categories like "No pain" approximately 0-1, mild, annoying in number 2, nagging in number 4, distressing in number 6, intense in number 8 and worst possible in number 10.

    Secondary Outcome Measures

    1. Biopsy [Interview 15 to 30 minutes at the end of the procedure]

      Evaluation of the discomfort or pain at the moment of the biopsy, that is, when the needle is inserted to take the samples in a 12-cylinder minimum or as needed, determined at the end of the procedure with Visual Analog Scale for Pain, The analogous visual scale used for this study measures from 0 to 10 the intensity of pain with a series of "faces" that show the intensity in the pain experimentation with categories such as "No pain" approximately 0-1, mild, annoying in number 2, annoying in number 4, distressing in number 6, intense in number 8 and worse in number 10. The analogous visual scale used for this study measures from 0-10 the intensity of the pain with a series of "faces" that show the intensity in the pain experimentation with categories like "No pain" approximately 0-1, mild, annoying in number 2, nagging in number 4, distressing in number 6, intense in number 8 and worst possible in number 10.

    Other Outcome Measures

    1. General procedure [Interview 15 to 30 minutes at the end of the procedure]

      Evaluation of the discomfort or pain at the moment of the biopsy, that is, when the needle is inserted to take the samples in a 12-cylinder minimum or as needed, determined at the end of the procedure with Visual Analog Scale for Pain. The analogous visual scale used for this study measures from 0 to 10 the intensity of pain with a series of "faces" that show the intensity in the pain experimentation with categories such as "No pain" approximately 0-1, mild, annoying in number 2, annoying in number 4, distressing in number 6, intense in number 8 and worse in number 10.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Male patients older than 18 years with indication for trans rectal prostate biopsy
    Exclusion Criteria:
    • Bad intestinal preparation.

    • Painful anorectal pathologies.

    • Clotting disorders without previous assessment by hematology.

    • Acute prostatitis

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Edgar Beltran-Suarez Mexico City Aztcapotzalco Mexico 07300

    Sponsors and Collaborators

    • Instituto Mexicano del Seguro Social

    Investigators

    • Principal Investigator: EDGAR BELTRAN-SUAREZ, MD, HOSPITAL OF SPECIALTIES OF THE NATIONAL MEDICAL

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    EDGAR BELTRAN-SUAREZ, Dr Edgar Beltran-Suarez, Instituto Mexicano del Seguro Social
    ClinicalTrials.gov Identifier:
    NCT03442075
    Other Study ID Numbers:
    • R-2017-3501-61
    First Posted:
    Feb 22, 2018
    Last Update Posted:
    Mar 27, 2018
    Last Verified:
    Mar 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by EDGAR BELTRAN-SUAREZ, Dr Edgar Beltran-Suarez, Instituto Mexicano del Seguro Social
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 27, 2018